Argenica Therapeutics Ltd
Argenica Therapeutics Ltd
Your view on AGN.AX
Overview
What the company does, where it operates, and who runs it.
About Argenica Therapeutics Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Liz Dallimore
- Headquarters
- 117 Broadway, Nedlands, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Liz Dallimore
- Headquarters
- 117 Broadway, Nedlands, WA, AU
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Argenica Therapeutics Ltd, and the rating behind it. AGN.AX last traded at AUD 0.17; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Argenica Therapeutics Ltd. Starting points for Argenica Therapeutics Ltd: EPS -AUD 0.08, beta 0.71 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Argenica Therapeutics Ltd. Trailing twelve-month EPS for Argenica Therapeutics Ltd stands at -AUD 0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Argenica Therapeutics Ltd valued side by side against its closest peers. Argenica Therapeutics Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Argenica Therapeutics Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Argenica Therapeutics Ltd executives and directors. Shares of Argenica Therapeutics Ltd have traded between AUD 0.09 and AUD 0.77 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Argenica Therapeutics Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Argenica Therapeutics Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Argenica Therapeutics Ltd. Coverage tracks Argenica Therapeutics Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.